145 related articles for article (PubMed ID: 33456709)
1. Combination therapies for MPNSTs targeting RABL6A-RB1 signaling.
Kohlmeyer JL; Gordon DJ; Tanas MR; Dodd RD; Monga V; Darbro BW; Quelle DE
Oncotarget; 2021 Jan; 12(1):10-14. PubMed ID: 33456709
[TBL] [Abstract][Full Text] [Related]
2. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
Kohlmeyer JL; Lingo JJ; Kaemmer CA; Scherer A; Warrier A; Voigt E; Raygoza Garay JA; McGivney GR; Brockman QR; Tang A; Calizo A; Pollard K; Zhang X; Hirbe AC; Pratilas CA; Leidinger M; Breheny P; Chimenti MS; Sieren JC; Monga V; Tanas MR; Meyerholz DK; Darbro BW; Dodd RD; Quelle DE
Clin Cancer Res; 2023 Sep; 29(17):3484-3497. PubMed ID: 37410426
[TBL] [Abstract][Full Text] [Related]
4. RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Kohlmeyer JL; Kaemmer CA; Umesalma S; Gourronc FA; Klingelhutz AJ; Quelle DE
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065204
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.
Kohlmeyer JL; Kaemmer CA; Lingo JJ; Voigt E; Leidinger MR; McGivney GR; Scherer A; Koppenhafer SL; Gordon DJ; Breheny P; Meyerholz DK; Tanas MR; Dodd RD; Quelle DE
Neurooncol Adv; 2022; 4(1):vdac047. PubMed ID: 35571990
[TBL] [Abstract][Full Text] [Related]
6. FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy.
Voigt E; Quelle DE
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686402
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response.
Gu Y; Wang W; Li Y; Li H; Guo Z; Wei C; Long M; Chung M; Aimaier R; Li Q; Wang Z
Front Oncol; 2022; 12():903177. PubMed ID: 35875109
[TBL] [Abstract][Full Text] [Related]
8. The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents.
González-Muñoz T; Kim A; Ratner N; Peinado H
Clin Cancer Res; 2022 Aug; 28(15):3185-3195. PubMed ID: 35446392
[TBL] [Abstract][Full Text] [Related]
9. RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.
Hagen J; Muniz VP; Falls KC; Reed SM; Taghiyev AF; Quelle FW; Gourronc FA; Klingelhutz AJ; Major HJ; Askeland RW; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR; Darbro BW; Quelle DE
Cancer Res; 2014 Nov; 74(22):6661-70. PubMed ID: 25273089
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
11. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
Umesalma S; Kaemmer CA; Kohlmeyer JL; Letney B; Schab AM; Reilly JA; Sheehy RM; Hagen J; Tiwari N; Zhan F; Leidinger MR; O'Dorisio TM; Dillon J; Merrill RA; Meyerholz DK; Perl AL; Brown BJ; Braun TA; Scott AT; Ginader T; Taghiyev AF; Zamba GK; Howe JR; Strack S; Bellizzi AM; Narla G; Darbro BW; Quelle FW; Quelle DE
J Clin Invest; 2019 Mar; 129(4):1641-1653. PubMed ID: 30721156
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract][Full Text] [Related]
13. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
[TBL] [Abstract][Full Text] [Related]
14. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
15. Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors.
Kahen EJ; Brohl A; Yu D; Welch D; Cubitt CL; Lee JK; Chen Y; Yoder SJ; Teer JK; Zhang YO; Wallace MR; Reed DR
Oncotarget; 2018 Apr; 9(32):22571-22585. PubMed ID: 29854299
[TBL] [Abstract][Full Text] [Related]
16.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
17. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.
Ki DH; He S; Rodig S; Look AT
Oncogene; 2017 Feb; 36(8):1058-1068. PubMed ID: 27477693
[TBL] [Abstract][Full Text] [Related]
19. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.
Grit JL; Pridgeon MG; Essenburg CJ; Wolfrum E; Madaj ZB; Turner L; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32245042
[TBL] [Abstract][Full Text] [Related]
20. CDK4 inhibitors an emerging strategy for the treatment of melanoma.
Lee B; McArthur GA
Melanoma Manag; 2015 Aug; 2(3):255-266. PubMed ID: 30190853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
